CRSP
Crispr Therapeutics AG
55.80$
-5.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 63.4% | 98.4% | 92.8% | 91.5% | 95.4% | 92.6% | 93.9% | 87.8% | 82.6% | 85.6% | 86.4% | 87.7% | |
| 61.9% | 97.8% | 91.5% | 88.4% | 93.4% | 88.5% | 63.9% | 33.5% | 9.4% | 17.5% | 13.3% | 15.7% | |
| 61.9% | 97.8% | 91.5% | 88.4% | 93.4% | 88.5% | 92.5% | 86.5% | 80.9% | 76.0% | 84.9% | 87.2% | |
| 196.5% | 0.2% | 0.9% | 1.0% | 0.0% | 0.0% | 0.6% | 0.0% | 0.5% | 9.0% | 1.1% | 0.0% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | -0.5% | – | – | – | |
| – | 0.8% | 6.1% | 6.9% | 3.8% | 6.8% | 2.3% | 5.0% | 7.3% | – | – | – | |
| – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 33.3% | 0.3% | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | |
| 556.7% | 118.3% | 32.5% | 30.8% | 19.8% | 11.9% | 9.0% | 12.8% | 16.4% | 15.6% | 13.8% | 15.2% | |
| 140.5% | 6.4% | 6.4% | 5.3% | 5.7% | 5.4% | 5.2% | 4.4% | 5.4% | 4.9% | 3.9% | 6.6% | |
| 2,488.5% | 24.0% | 17.5% | 16.3% | 7.2% | 0.8% | 0.6% | 0.4% | 0.7% | 0.7% | 0.8% | 0.8% | |
| 13.8% | 1.0% | 1.3% | 0.6% | 1.0% | 0.6% | 0.5% | 0.5% | 1.2% | 1.7% | 0.7% | 0.5% | |
| 2,488.5% | 24.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| -466.1% | -18.3% | 67.5% | 69.2% | 80.2% | 88.1% | 91.0% | 87.2% | 83.6% | 84.4% | 86.2% | 84.8% | |
| -550.3% | -21.3% | -16.5% | -46.2% | -59.6% | -21.1% | -31.4% | -7.1% | -37.7% | -44.8% | -60.9% | -86.0% | |
| 1,918.7% | 18.4% | 3.6% | 14.8% | 9.8% | 5.3% | 3.6% | 2.9% | 3.5% | 3.6% | 3.8% | 4.0% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.